HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CYT997 causes apoptosis in human multiple myeloma.

Abstract
Multiple Myeloma (MM) is an incurable malignancy of mature plasma cells. Microtubule targeting agents (MTAs) are an established class of drug that include many conventional and some novel compounds. MTAs function by inhibiting the polymerisation or depolymerisation of microtubules (MTs) within the cell, disrupting various important cellular functions. We have investigated pre-clinically the novel tubulin polymerisation inhibitor CYT997 for the potential treatment of MM. Here we demonstrate the promising anti-myeloma activity of CYT997 as evidenced by tubulin disruption, inhibition of growth and proliferation, cell cycle arrest and most importantly apoptosis of both human myeloma cell lines (HMCLs) and primary MM cells using nanomolar drug concentrations. CYT997 also synergises with bortezomib to produce more potent anti-MM activity. These in vitro observations were validated in vivo by the ability of CYT997 to significantly prolong survival in a murine model of aggressive systemic myelomatosis. These findings provide a basis for continuing pre-clinical and clinical investigations into the anti-MM effects of CYT997.
AuthorsKatherine Monaghan, Tiffany Khong, Gregg Smith, Andrew Spencer
JournalInvestigational new drugs (Invest New Drugs) Vol. 29 Issue 2 Pg. 232-8 (Apr 2011) ISSN: 1573-0646 [Electronic] United States
PMID19907921 (Publication Type: Journal Article)
Chemical References
  • Boronic Acids
  • CYT997
  • Pyrazines
  • Pyridines
  • Pyrimidines
  • Tubulin
  • Bortezomib
Topics
  • Animals
  • Apoptosis (drug effects)
  • Boronic Acids (pharmacology)
  • Bortezomib
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • Fluorescent Antibody Technique
  • G2 Phase (drug effects)
  • Humans
  • Mice
  • Mitosis (drug effects)
  • Multiple Myeloma (pathology)
  • Polymerization (drug effects)
  • Pyrazines (pharmacology)
  • Pyridines (pharmacology)
  • Pyrimidines (pharmacology)
  • Survival Analysis
  • Time Factors
  • Tubulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: